New study reveals how psoriasis drug enters breast milk
NCT ID NCT06476834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 study looked at how much deucravacitinib (SOTYKTU®), a drug for plaque psoriasis, passes into breast milk. Eight healthy lactating women took a single dose, and researchers measured drug levels in their milk and blood. The goal was to estimate how much of the drug a nursing infant might consume, helping guide future recommendations for breastfeeding mothers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Deucravacitinib (SOTYKTU®)
- What this could lead to
- If successful, this study could help doctors understand how much deucravacitinib passes into breast milk, guiding safer use during breastfeeding.
- What could go wrong
- This is a very small study (8 participants) in healthy volunteers, not patients. Results may not apply to all women or those with medical conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Las Vegas, Nevada, 89113-2246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults